Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer – results of the MRC randomised controlled trial

A Cuschieri (Corresponding Author), V Joypaul, P Fayers, P Cook, J Fielding, J Craven, J Bancewicz

Research output: Contribution to journalArticle

829 Citations (Scopus)

Abstract

Background In Japan the surgical approach to treatment of potentially curable gastric cancer, including extended lymphadenectomy, seems in retrospective surveys to give better results than the less radical procedures favoured in Western countries. There has, however, been no evidence from randomised trials that extended lymphadenectomy (D2 gastric resection) confers a survival advantage. This question was addressed in a trial involving thirty-two surgeons in Europe. Methods In a prospective randomised controlled trial, D1 resection (level 1 lymphadenectomy) was compared with D2 resection (levels 1 and 2 lymphadenectomy). Central randomisation (200 patients in each arm) followed a staging laparotomy. Findings The D2 group had greater postoperative hospital mortality (13% vs 6·5%; p=0·04 [95% Cl 9-18% for D2, 4-11% for D1] and higher overall postoperative morbidity (46% vs 28%; p<0·001); their postoperative stay was also longer. The excess postoperative morbidity and mortality in the D2 group was accounted for by distal pancreaticosplenectomy and splenectomy. In the whole group (400 patients), survival beyond three years was 30% in patients whose gastrectomy included en-bloc pancreatico-splenic resection versus 50% in the remainder. Interpretation D2 gastric resections are followed by higher morbidity and mortality than D1 resections. These disadvantages are consequent upon additional pancreatectomies and distal splenectomies, and in long-term follow-up the higher mortality when the pancreas and spleen are resected may prove to nullify any survival benefit from D2 procedures.
Original languageEnglish
Pages (from-to)995-999
Number of pages5
JournalThe Lancet
Volume347
Issue number9007
DOIs
Publication statusPublished - 13 Apr 1996

Fingerprint

Lymph Node Excision
Stomach Neoplasms
Randomized Controlled Trials
Morbidity
Mortality
Splenectomy
Survival
Stomach
Pancreatectomy
Gastrectomy
Random Allocation
Hospital Mortality
Laparotomy
Pancreas
Japan
Spleen
Therapeutics

Cite this

Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer – results of the MRC randomised controlled trial. / Cuschieri, A (Corresponding Author); Joypaul, V ; Fayers, P; Cook, P ; Fielding, J; Craven, J; Bancewicz, J .

In: The Lancet, Vol. 347, No. 9007, 13.04.1996, p. 995-999.

Research output: Contribution to journalArticle

Cuschieri, A ; Joypaul, V ; Fayers, P ; Cook, P ; Fielding, J ; Craven, J ; Bancewicz, J . / Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer – results of the MRC randomised controlled trial. In: The Lancet. 1996 ; Vol. 347, No. 9007. pp. 995-999.
@article{1db2c32cab574b219f13e8ee4af4cd6f,
title = "Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer – results of the MRC randomised controlled trial",
abstract = "Background In Japan the surgical approach to treatment of potentially curable gastric cancer, including extended lymphadenectomy, seems in retrospective surveys to give better results than the less radical procedures favoured in Western countries. There has, however, been no evidence from randomised trials that extended lymphadenectomy (D2 gastric resection) confers a survival advantage. This question was addressed in a trial involving thirty-two surgeons in Europe. Methods In a prospective randomised controlled trial, D1 resection (level 1 lymphadenectomy) was compared with D2 resection (levels 1 and 2 lymphadenectomy). Central randomisation (200 patients in each arm) followed a staging laparotomy. Findings The D2 group had greater postoperative hospital mortality (13{\%} vs 6·5{\%}; p=0·04 [95{\%} Cl 9-18{\%} for D2, 4-11{\%} for D1] and higher overall postoperative morbidity (46{\%} vs 28{\%}; p<0·001); their postoperative stay was also longer. The excess postoperative morbidity and mortality in the D2 group was accounted for by distal pancreaticosplenectomy and splenectomy. In the whole group (400 patients), survival beyond three years was 30{\%} in patients whose gastrectomy included en-bloc pancreatico-splenic resection versus 50{\%} in the remainder. Interpretation D2 gastric resections are followed by higher morbidity and mortality than D1 resections. These disadvantages are consequent upon additional pancreatectomies and distal splenectomies, and in long-term follow-up the higher mortality when the pancreas and spleen are resected may prove to nullify any survival benefit from D2 procedures.",
author = "A Cuschieri and V Joypaul and P Fayers and P Cook and J Fielding and J Craven and J Bancewicz",
year = "1996",
month = "4",
day = "13",
doi = "10.5555/uri:pii:S0140673696901440",
language = "English",
volume = "347",
pages = "995--999",
journal = "The Lancet",
issn = "0140-6736",
publisher = "ACADEMIC PRESS INC ELSEVIER SCIENCE",
number = "9007",

}

TY - JOUR

T1 - Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer – results of the MRC randomised controlled trial

AU - Cuschieri, A

AU - Joypaul, V

AU - Fayers, P

AU - Cook, P

AU - Fielding, J

AU - Craven, J

AU - Bancewicz, J

PY - 1996/4/13

Y1 - 1996/4/13

N2 - Background In Japan the surgical approach to treatment of potentially curable gastric cancer, including extended lymphadenectomy, seems in retrospective surveys to give better results than the less radical procedures favoured in Western countries. There has, however, been no evidence from randomised trials that extended lymphadenectomy (D2 gastric resection) confers a survival advantage. This question was addressed in a trial involving thirty-two surgeons in Europe. Methods In a prospective randomised controlled trial, D1 resection (level 1 lymphadenectomy) was compared with D2 resection (levels 1 and 2 lymphadenectomy). Central randomisation (200 patients in each arm) followed a staging laparotomy. Findings The D2 group had greater postoperative hospital mortality (13% vs 6·5%; p=0·04 [95% Cl 9-18% for D2, 4-11% for D1] and higher overall postoperative morbidity (46% vs 28%; p<0·001); their postoperative stay was also longer. The excess postoperative morbidity and mortality in the D2 group was accounted for by distal pancreaticosplenectomy and splenectomy. In the whole group (400 patients), survival beyond three years was 30% in patients whose gastrectomy included en-bloc pancreatico-splenic resection versus 50% in the remainder. Interpretation D2 gastric resections are followed by higher morbidity and mortality than D1 resections. These disadvantages are consequent upon additional pancreatectomies and distal splenectomies, and in long-term follow-up the higher mortality when the pancreas and spleen are resected may prove to nullify any survival benefit from D2 procedures.

AB - Background In Japan the surgical approach to treatment of potentially curable gastric cancer, including extended lymphadenectomy, seems in retrospective surveys to give better results than the less radical procedures favoured in Western countries. There has, however, been no evidence from randomised trials that extended lymphadenectomy (D2 gastric resection) confers a survival advantage. This question was addressed in a trial involving thirty-two surgeons in Europe. Methods In a prospective randomised controlled trial, D1 resection (level 1 lymphadenectomy) was compared with D2 resection (levels 1 and 2 lymphadenectomy). Central randomisation (200 patients in each arm) followed a staging laparotomy. Findings The D2 group had greater postoperative hospital mortality (13% vs 6·5%; p=0·04 [95% Cl 9-18% for D2, 4-11% for D1] and higher overall postoperative morbidity (46% vs 28%; p<0·001); their postoperative stay was also longer. The excess postoperative morbidity and mortality in the D2 group was accounted for by distal pancreaticosplenectomy and splenectomy. In the whole group (400 patients), survival beyond three years was 30% in patients whose gastrectomy included en-bloc pancreatico-splenic resection versus 50% in the remainder. Interpretation D2 gastric resections are followed by higher morbidity and mortality than D1 resections. These disadvantages are consequent upon additional pancreatectomies and distal splenectomies, and in long-term follow-up the higher mortality when the pancreas and spleen are resected may prove to nullify any survival benefit from D2 procedures.

U2 - 10.5555/uri:pii:S0140673696901440

DO - 10.5555/uri:pii:S0140673696901440

M3 - Article

VL - 347

SP - 995

EP - 999

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9007

ER -